What are the indications for stopping immunosuppressive therapy?

Indications to Stop Immunosuppressive Therapy

Immunosuppressive therapy should be discontinued based on the specific clinical context: for autoimmune hepatitis after achieving sustained biochemical and histological remission for at least 24 months; for immune checkpoint inhibitor toxicities when grade 3-4 organ toxicity occurs (permanently); and for lupus nephritis after ≥36 months of total treatment with sustained complete remission.

Context-Specific Discontinuation Criteria

Autoimmune Hepatitis

Stop immunosuppression when ALL of the following are met 1:

• Normal serum AST/ALT, total bilirubin, and γ-globulin/IgG levels
• Normal liver histology without inflammatory activity on biopsy
• Minimum 24 months of continuous therapy
• Biochemical remission maintained for at least 12 months on low-dose therapy

Critical caveat: Relapse occurs in approximately 80% of patients after drug withdrawal 1. Patients who relapse multiply have significantly worse outcomes—38% progress to cirrhosis versus 4% who maintain remission (P=0.004), and 20% die from liver failure or require transplantation versus 0% (P=0.008) 1. The number of relapse episodes directly correlates with disease progression and adverse outcomes.

Predictors favoring successful withdrawal 2:

• Identifiable initial disease trigger
• Absence of other autoimmune diseases
• Shorter time to biochemical remission
• Normal transaminases at withdrawal

Immune Checkpoint Inhibitor Toxicities

Permanent discontinuation is mandatory for 3:

• Grade 4 toxicities (any organ system)
• Grade 3-4 pneumonitis
• Grade 3-4 hepatitis (AST/ALT >5x ULN)
• Grade 3-4 colitis/diarrhea (≥7 stools/day over baseline)
• Grade 4 skin reactions
• Any grade myocarditis
• Severe neurological toxicity (Guillain-Barré, myasthenia-like syndromes)

Temporary interruption (may resume if improves to ≤grade 1) 3, 4:

• Grade 2 toxicities after corticosteroid treatment and symptom resolution
• Grade 1 symptomatic endocrinopathies

Key principle: For grade ≥2 colitis, permanently discontinue CTLA-4 agents; may restart PD-1/PD-L1 agents only if recovery to ≤grade 1 with concurrent immunosuppressant maintenance if clinically indicated 4.

Lupus Nephritis

Consider discontinuation after 5, 6:

• ≥36 months total immunosuppression (initial + maintenance therapy)
• Sustained complete renal response for ≥12 months
• No ongoing extrarenal SLE activity
• Gradual tapering of glucocorticoids first, then immunosuppressive drugs over several months

Evidence supporting this timeline 5:

• Most renal flares occur within first 5-6 years after treatment initiation
• 28-50% of patients show persistent histologic activity despite ≥36 months of therapy and ≥12 months of complete clinical response
• Patients with persistent histologic activity have increased flare risk after discontinuation
• Longer treatment duration and longer remission duration reduce flare risk

Consider repeat kidney biopsy before withdrawal to assess for residual inflammatory activity 5, 6. Proteinuria may reflect CKD rather than active disease in partial responders with resolved histologic activity.

Glomerulonephritis (Non-Lupus)

For membranous nephropathy after cyclical therapy 7:

• Manage conservatively for at least 6 months after completing 6-month cyclical regimen before declaring treatment failure
• Exception: rapidly deteriorating kidney function or severe/disabling nephrotic symptoms

For FSGS with cyclosporine 7:

• If partial/complete remission achieved, continue cyclosporine for at least 12 months, then slow taper
• Discontinue after 6 months if no response

Bullous Pemphigoid

Discontinue when 8:

• Symptom-free for 1-6 months on minimal therapy (prednisone ≤0.1 mg/kg/day or clobetasol propionate ≤10g/week)
• Average treatment duration: 4-12 months depending on disease severity
• Consider patient's overall condition and comorbidities

Warning: Positive direct immunofluorescence or BP180 ELISA >27 U/mL indicates increased relapse risk 8. Monitor for adrenal insufficiency even after topical steroid use.

Common Pitfalls to Avoid

1. Premature withdrawal in autoimmune hepatitis: The 60-80% relapse rate in children and 80% in adults demands strict adherence to remission criteria before attempting withdrawal 1, 2.

2. Resuming checkpoint inhibitors after grade 3-4 toxicity: This risks life-threatening recurrence, particularly with pneumonitis, myocarditis, or hepatitis 3.

3. Abrupt cessation: Always taper gradually over 4-6 weeks to months depending on the condition 3, 5, 6, 8. Abrupt withdrawal increases relapse risk.

4. Ignoring histological remission: Clinical and biochemical remission does not guarantee histological remission. Liver or kidney biopsy should guide withdrawal decisions in autoimmune hepatitis and lupus nephritis 1, 5.

5. Inadequate monitoring post-withdrawal: Follow-up at 3 months post-discontinuation is critical for detecting relapses 8. For autoimmune hepatitis, monitor liver tests at 4-6 week intervals during and after tapering 1.